Repository logo
 

Plasma adiponectin levels and risk of heart failure, atrial fibrillation, aortic valve stenosis, and myocardial infarction: large-scale observational and Mendelian randomization evidence.

Accepted version
Peer-reviewed

Change log

Authors

Nielsen, Maria Booth 
Çolak, Yunus 
Mason, Amy 

Abstract

AIMS: Adiponectin may play an important protective role in heart failure and associated cardiovascular diseases. We hypothesized that plasma adiponectin is associated observationally and causally, genetically with risk of heart failure, atrial fibrillation, aortic valve stenosis, and myocardial infarction. METHODS AND RESULTS: In the Copenhagen General Population Study, we examined 30 045 individuals with plasma adiponectin measurements observationally and 96 903 individuals genetically in one-sample Mendelian randomization analyses using five genetic variants explaining 3% of the variation in plasma adiponectin. In the HERMES, UK Biobank, The Nord-Trøndelag Health Study (HUNT), deCODE, the Michigan Genomics Initiative (MGI), DiscovEHR, and the AFGen consortia, we performed two-sample Mendelian randomization analyses in up to 1 030 836 individuals using 12 genetic variants explaining 14% of the variation in plasma adiponectin.In observational analyses modelled linearly, a 1 unit log-transformed higher plasma adiponectin was associated with a hazard ratio of 1.51 (95% confidence interval: 1.37-1.66) for heart failure, 1.63 (1.50-1.78) for atrial fibrillation, 1.21 (1.03-1.41) for aortic valve stenosis, and 1.03 (0.93-1.14) for myocardial infarction; levels above the median were also associated with an increased risk of myocardial infarction, and non-linear U-shaped associations were more apparent for heart failure, aortic valve stenosis, and myocardial infarction in less-adjusted models. Corresponding genetic, causal risk ratios were 0.92 (0.65-1.29), 0.87 (0.68-1.12), 1.55 (0.87-2.76), and 0.93 (0.67-1.30) in one-sample Mendelian randomization analyses, and no significant associations were seen for non-linear one-sample Mendelian randomization analyses; corresponding causal risk ratios were 0.99 (0.89-1.09), 1.00 (0.92-1.08), 1.01 (0.79-1.28), and 0.99 (0.86-1.13) in two-sample Mendelian randomization analyses, respectively. CONCLUSION: Observationally, elevated plasma adiponectin was associated with an increased risk of heart failure, atrial fibrillation, aortic valve stenosis, and myocardial infarction. However, genetic evidence did not support causality for these associations.

Description

Keywords

Adiponectin, Aortic valve stenosis, Atrial fibrillation, Genetic polymorphisms, Heart failure, Myocardial infarction, Humans, Adiponectin, Aortic Valve Stenosis, Atrial Fibrillation, Genome-Wide Association Study, Heart Failure, Mendelian Randomization Analysis, Myocardial Infarction, Polymorphism, Single Nucleotide, Risk Factors

Journal Title

Cardiovasc Res

Conference Name

Journal ISSN

0008-6363
1755-3245

Volume Title

Publisher

Oxford University Press (OUP)
Sponsorship
Wellcome Trust (225790/Z/22/Z)
Wellcome Trust (225790/Z/22/Z)
Medical Research Council (MC_UU_00002/7)
British Heart Foundation (RG/18/13/33946)
British Heart Foundation (RE/18/1/34212)
National Institute for Health and Care Research (IS-BRC-1215-20014)
British Heart Foundation (None)
Wellcome Trust (100114/Z/12/Z)
Wellcome Trust (204623/Z/16/Z)